Can a new tracer spot prostate cancer return better than the standard scan?

NCT ID NCT06907641

Completed Diagnosis Sponsor: St Vincent's Hospital, Sydney Source: ClinicalTrials.gov ↗

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This trial tests whether a new PET/CT tracer, 64Cu-SAR-bisPSMA, can find more sites of prostate cancer recurrence than the standard 68Ga PSMA-11 scan in men whose PSA rises after prostate removal. Fifty men will receive both scans, and researchers will compare how many lesions each detects and how accurate they are. The goal is to see if the new tracer could improve planning for salvage radiotherapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 64Cu-SAR-bisPSMA, a radioactive tracer for PET/CT imaging
What this could lead to: If this tracer detects more cancer spots than the standard scan, it could help doctors plan more precise salvage therapy for men with rising PSA after prostatectomy.
What could go wrong: This is a small, early-phase study, so results may not apply broadly. The new tracer may not clearly outperform the standard scan, and radiation exposure is a consideration.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER (POST PROSTATECTOMY) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER (POST PROSTATECTOMY)

Contacts and locations

Locations

St Vincent's Hospital, Sydney

Darlinghurst, New South Wales, 2010, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.